116 related articles for article (PubMed ID: 35104698)
1. SiRNA-circFARSA-loaded porous silicon nanomaterials for pancreatic cancer treatment via inhibition of CircFARSA expression.
Yuan H; Huang X; Li Q; Luo C; Lin C; Zhang S; Zhang Y; Yan Z; Du N; Liu Z; Jiang H; Chen B
Biomed Pharmacother; 2022 Mar; 147():112672. PubMed ID: 35104698
[TBL] [Abstract][Full Text] [Related]
2. Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.
Tong WY; Alnakhli M; Bhardwaj R; Apostolou S; Sinha S; Fraser C; Kuchel T; Kuss B; Voelcker NH
J Nanobiotechnology; 2018 Apr; 16(1):38. PubMed ID: 29653579
[TBL] [Abstract][Full Text] [Related]
3. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K
Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594
[TBL] [Abstract][Full Text] [Related]
4. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
5. Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.
Yang J; Zhao R; Feng Q; Zhuo X; Wang R
Invest New Drugs; 2021 Feb; 39(1):66-76. PubMed ID: 32794135
[TBL] [Abstract][Full Text] [Related]
6.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
7. Cancer-targeting siRNA delivery from porous silicon nanoparticles.
Wan Y; Apostolou S; Dronov R; Kuss B; Voelcker NH
Nanomedicine (Lond); 2014 Oct; 9(15):2309-21. PubMed ID: 24593001
[TBL] [Abstract][Full Text] [Related]
8. The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells.
Zhong Y; Xia Z; Liu J; Lin Y; Zan H
Oncol Rep; 2012 Apr; 27(4):1003-10. PubMed ID: 22200969
[TBL] [Abstract][Full Text] [Related]
9. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer.
Ocker M; Neureiter D; Lueders M; Zopf S; Ganslmayer M; Hahn EG; Herold C; Schuppan D
Gut; 2005 Sep; 54(9):1298-308. PubMed ID: 16099798
[TBL] [Abstract][Full Text] [Related]
10. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
Liu JP; Yuan SZ; Zhang SN
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
[TBL] [Abstract][Full Text] [Related]
11. Sustained small interfering RNA delivery by mesoporous silicon particles.
Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M
Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760
[TBL] [Abstract][Full Text] [Related]
12. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
14. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
16. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
17. The Use of Star Polymer Nanoparticles for the Delivery of siRNA to Mouse Orthotopic Pancreatic Tumor Models.
McCarroll JA; Sharbeen G; Kavallaris M; Phillips PA
Methods Mol Biol; 2019; 1974():329-353. PubMed ID: 31099013
[TBL] [Abstract][Full Text] [Related]
18. Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo.
Tao H; Xu H; Zuo L; Li C; Qiao G; Guo M; Zheng L; Leitgeb M; Lin X
Int J Biol Macromol; 2020 Oct; 161():470-480. PubMed ID: 32531356
[TBL] [Abstract][Full Text] [Related]
19. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y
Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
[TBL] [Abstract][Full Text] [Related]
20. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
